Search

Your search keyword '"Suzanne E. Dahlberg"' showing total 222 results

Search Constraints

Start Over You searched for: Author "Suzanne E. Dahlberg" Remove constraint Author: "Suzanne E. Dahlberg"
222 results on '"Suzanne E. Dahlberg"'

Search Results

1. Binge-eating behaviors in adolescents and young adults during the COVID-19 pandemic

2. Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

3. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

4. Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome

5. Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib

6. Real‐world feasibility of short‐term, unsupervised home spirometry in CF

8. Table S2 from Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

11. Figure S1 from Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

12. Supplementary Methods, Figure Legends 1-4 from Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation

14. Interview with Dr. Weinstock from Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation

15. Supplementary Figure 2 from Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation

16. Data from Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

17. Supplemental Methods from Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

18. Supplementary Figure 1 from Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation

19. Supplementary Figure 4 from Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation

20. Supplementary Figure 3 from Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation

23. Supplemental Tables 1-3, Supplementary Figure Legends from Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer

25. Figure S1: CONSORT diagram. from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

26. Figure S2: Screening with drugs compared with DMSO control. from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

27. Data from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

30. Figure S3 from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

32. Supplemental Figure 2 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

33. Supplemental Figure 1 from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

35. Supplementary Table S1 from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

36. Supplementary Tables 1-3 from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

37. Data from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

38. Data from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

40. Supplemental Legend from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

41. Supplemental Figure 1 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

42. Efficacy and Safety of High-dose Cholecalciferol in Patients With Inflammatory Bowel Disease Receiving Infliximab

44. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

45. Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial

46. Bone Density and Bone Marrow Composition in Transgender Girls Prior to Pubertal Blockade: A Case Series

47. Is Ovarian Reserve Impacted in Anorexia Nervosa?

48. Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

49. Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

50. Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase–rearranged Advanced Non–Small Cell Lung Cancer Patients Treated With Crizotinib

Catalog

Books, media, physical & digital resources